Arcus Biosciences (NYSE:RCUS) Shares Up 3.2% – Still a Buy?

Posted by Stanley Muller on Sep 23rd, 2026

Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report) shot up 3.2% during mid-day trading on Wednesday . The stock traded as high as $27.00 and last traded at $27.7420. 50,210 shares changed hands during mid-day trading, a decline of 96% from the average session volume of 1,277,369 shares. The stock had previously closed at $26.87.

Analysts Set New Price Targets

RCUS has been the topic of a number of recent analyst reports. Lifesci Capital initiated coverage on shares of Arcus Biosciences in a research report on Thursday, June 4th. They set an “outperform” rating and a $46.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcus Biosciences in a research note on Friday, September 11th. The Goldman Sachs Group reissued a “buy” rating and set a $42.00 target price on shares of Arcus Biosciences in a research report on Friday, August 7th. Wells Fargo & Company boosted their target price on Arcus Biosciences from $23.00 to $26.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 6th. Finally, Wedbush upped their target price on Arcus Biosciences from $41.00 to $43.00 and gave the company an “outperform” rating in a report on Thursday, August 6th. Ten investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $38.30.

Get Our Latest Research Report on Arcus Biosciences

Arcus Biosciences Trading Down 2.5%

The stock’s 50 day simple moving average is $28.33 and its two-hundred day simple moving average is $25.95. The stock has a market capitalization of $3.34 billion, a PE ratio of -6.71 and a beta of 0.81. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.82 and a quick ratio of 3.82.

Arcus Biosciences (NYSE:RCUS – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.17. Arcus Biosciences had a negative net margin of 393.16% and a negative return on equity of 89.54%. The company had revenue of $41.00 million during the quarter, compared to analyst estimates of $21.98 million. The company’s revenue was down 74.4% on a year-over-year basis. On average, sell-side analysts expect that Arcus Biosciences, Inc. will post -3.59 EPS for the current year.

Insiders Place Their Bets

In other Arcus Biosciences news, President Juan Jaen sold 20,067 shares of the business’s stock in a transaction on Friday, July 10th. The stock was sold at an average price of $28.62, for a total value of $574,317.54. Following the sale, the president directly owned 822,240 shares in the company, valued at $23,532,508.80. The trade was a 2.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Alexander Azoy sold 2,827 shares of the company’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $30.00, for a total value of $84,810.00. Following the transaction, the chief accounting officer directly owned 39,581 shares in the company, valued at $1,187,430. This represents a 6.67% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 71,396 shares of company stock valued at $2,116,613 over the last three months. Company insiders own 7.60% of the company’s stock.

Institutional Trading of Arcus Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the business. WINTON GROUP Ltd boosted its holdings in Arcus Biosciences by 59.7% in the 2nd quarter. WINTON GROUP Ltd now owns 52,398 shares of the company’s stock worth $1,615,000 after buying an additional 19,578 shares during the period. Integrated Wealth Concepts LLC bought a new stake in Arcus Biosciences during the 2nd quarter valued at $30,000. Arizona State Retirement System lifted its position in shares of Arcus Biosciences by 1.7% during the second quarter. Arizona State Retirement System now owns 24,211 shares of the company’s stock worth $746,000 after acquiring an additional 409 shares in the last quarter. Nykredit A S purchased a new stake in shares of Arcus Biosciences during the second quarter worth $134,000. Finally, Allianz Asset Management GmbH bought a new position in shares of Arcus Biosciences in the second quarter worth $2,542,000. Institutional investors own 92.89% of the company’s stock.

Arcus Biosciences Company Profile

(Get Free Report)

Arcus Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for cancer and other serious diseases. The company combines antibody-based therapies, small-molecule drugs and combination treatment strategies designed to influence the immune system and other biological pathways involved in tumor growth.

Its oncology pipeline includes investigational therapies targeting pathways such as TIGIT, PD-1, CD73, adenosine receptors and HIF-2α. Key programs have included domvanalimab, an anti-TIGIT antibody; zimberelimab, an anti-PD-1 antibody; quemliclustat, a CD73 inhibitor; etrumadenant, an adenosine receptor antagonist; and AB521, an HIF-2α inhibitor.